Waters Corp /De/ (WAT) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Total · absolute moveSwitch to Alpha · NYSE
Waters Corp /De/ (WAT) stock forecast summary
Our AI ranks Waters Corp /De/ outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Waters Corp /De/ is a large-cap company with a market capitalization of $42.17B. It ranks number 2 by market capitalization among the 25 Laboratory Analytical Instruments issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for WAT is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.9% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, WAT included.
Follow WAT freeWAT price chart and AI forecast
How WAT ranks among 5379 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Waters Corp /De/ (WAT) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Laboratory Analytical Instruments peers listed below that report each metric.
Reported net income does not reconcile with earnings per share and the share count, so net-income-based ratios are withheld.
Valuation & Market
| Metric | WAT | Rank |
|---|---|---|
| Market Cap | $42.17B | 2/25 |
| P/B Ratio | 2.77x | 10/23 |
| EPS | $4.87 | – |
| Book Value/Share | $154.66 | – |
| Revenue/Share | $47.27 | – |
Profitability & Margins
| Metric | WAT | Rank |
|---|---|---|
| ROIC | 1.5% | 4/21 |
| Operating Margin | 7.1% | 4/21 |
| EBT Margin | 4.4% | 6/22 |
| Tax Rate | 19.1% | – |
Financial Health
| Metric | WAT | Rank |
|---|---|---|
| Current Ratio | 1.86x | 19/25 |
| Quick Ratio | 1.29x | 20/24 |
| D/E Ratio | 0.63x | 10/24 |
| Financial Leverage | 1.63x | 10/24 |
| Working Capital | $2.07B | 2/25 |
Cash Flow
| Metric | WAT | Rank |
|---|---|---|
| Operating Cash Flow | $550M | 6/24 |
| OCF Growth YoY | -26.2% | 9/12 |
Operational Efficiency
| Metric | WAT | Rank |
|---|---|---|
| Asset Turnover | 0.19x | 19/21 |
| Receivables Turnover | 2.3x | 19/19 |
| Fixed Assets Turnover | 3.1x | 17/21 |
| Days Sales Outstanding | 156 days | 1/19 |
Income Statement
| Metric | WAT | Rank |
|---|---|---|
| Total Revenue | $4.64B | 3/21 |
| Operating Income | $329M | 4/21 |
| R&D Expense | $319M | 4/21 |
| SG&A Expense | $1.25B | 3/20 |
Dividend & Shareholder Information
| Metric | WAT | Rank |
|---|---|---|
| Shares Outstanding | 98M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $4.46B | 18.0% of assets |
| Cash & Short-term Investments | $539M | 2.2% of assets |
| Accounts Receivable | $1.99B | 8.0% of assets |
| Inventory | $1.38B | 5.6% of assets |
| Total Liabilities | $9.56B | 38.6% of assets |
| Short-term Debt | $1.54B | 6.2% of assets |
WAT quarterly financials and insider trading
Waters Corp /De/ (WAT) industry peers
Companies classified under the same SEC industry code as Waters Corp /De/ (Laboratory Analytical Instruments): 25 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| WAT Waters Corp /De/ | ▲ | $42.17B |
| A Agilent Technologies, Inc. | ▼ | $48.40B |
| ILMN Illumina, Inc. | ▶ | $40.95B |
| MTD Mettler Toledo International Inc/ | ▼ | $32.02B |
| RVTY Revvity, Inc. | ▶ | $17.30B |
| AVTR Avantor, Inc. | ▶ | $10.62B |
| BIO Bio-Rad Laboratories, Inc. | ▼ | $9.73B |
| TXG 10x Genomics, Inc. | ▲ | $9.35B |
| BRKR Bruker Corp | ▲ | $8.56B |
| ALMR Alamar Biosciences, Inc. | ▶ | $1.63B |
| CTKB Cytek Biosciences, Inc. | ▲ | $695M |
| PACB Pacific Biosciences Of California, Inc. | ▲ | $637M |
| MASS 908 Devices Inc. | ▲ | $500M |
| EYPT Eyepoint, Inc. | ▲ | $265M |
| NAUT Nautilus Biotechnology, Inc. | ▲ | $261M |
| BFNH Bioforce Nanosciences Holdings, Inc. | ▼ | $250M |
| QTRX Quanterix Corp | ▲ | $149M |
| SEER Seer, Inc. | ▶ | $119M |
| RPID Rapid Micro Biosystems, Inc. | ▲ | $44M |
| PRPO Precipio, Inc. | ▶ | $40M |
| HBIO Harvard Bioscience Inc | ▼ | $38M |
| BNGO Bionano Genomics, Inc. | ▲ | $16M |
| LCTC Lifeloc Technologies, Inc | ▼ | $11M |
| ASTC Astrotech Corp | ▶ | $11M |
| SCND Scientific Industries Inc | ▶ | $8M |
Where WAT sits on the market map
Waters Corp /De/ (WAT) stock news
Loading...
Waters Corp /De/ (WAT) stock forecast FAQ
What is the Waters Corp /De/ (WAT) stock forecast?
Our AI ranks Waters Corp /De/ outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Waters Corp /De/ stock predictions?
A per-ticker accuracy statistic for WAT is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Waters Corp /De/ forecasts updated?
Waters Corp /De/ forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Waters Corp /De/'s industry peers?
25 issuers in our coverage, WAT included, share the SEC industry code Laboratory Analytical Instruments. The largest are: Agilent Technologies, Inc. (A), Illumina, Inc. (ILMN), Mettler Toledo International Inc/ (MTD), Revvity, Inc. (RVTY), Avantor, Inc. (AVTR), Bio-Rad Laboratories, Inc. (BIO).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.